Detalles de la búsqueda
1.
Treatment patterns and clinical outcomes in patients with metastatic triple-negative breast cancer: a large-scale data analysis using the Japanese claims database.
Breast Cancer Res Treat
; 2024 May 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38704772
2.
Changes in cell-free DNA after short-term palbociclib and fulvestrant treatment for advanced or metastatic hormone receptor-positive and human epidermal growth factor 2-negative breast cancer.
Breast Cancer Res Treat
; 203(2): 225-234, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37875670
3.
Treatment patterns, healthcare resource utilization and outcomes for early stage triple-negative breast cancer in Japan.
Future Oncol
; 20(13): 833-849, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38305038
4.
Protecting the Brain: Novel Strategies for Preventing Breast Cancer Brain Metastases through Selective Estrogen Receptor ß Agonists and In Vitro Blood-Brain Barrier Models.
Int J Mol Sci
; 25(6)2024 Mar 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38542355
5.
[Improved Outcomes in Advanced Metastatic Breast Cancer].
Gan To Kagaku Ryoho
; 51(3): 250-253, 2024 Mar.
Artículo
en Japonés
| MEDLINE | ID: mdl-38494802
6.
Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor ß.
Breast Cancer Res
; 25(1): 41, 2023 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37059993
7.
Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.
Breast Cancer Res Treat
; 201(3): 397-408, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37479943
8.
Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial).
Breast Cancer Res Treat
; 199(2): 253-263, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37000345
9.
A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer.
Breast Cancer Res Treat
; 202(3): 485-496, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37676450
10.
TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.
Future Oncol
; 19(35): 2349-2359, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37526149
11.
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Jpn J Clin Oncol
; 53(1): 4-15, 2023 Jan 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36398439
12.
Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 53(3): 203-211, 2023 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484305
13.
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(5): 636-649, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405087
14.
Evaluation of a novel medical device for pegfilgrastim administration.
Cancer Sci
; 113(5): 1763-1770, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35293085
15.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Cancer Sci
; 113(9): 3169-3179, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35754298
16.
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Breast Cancer Res Treat
; 191(3): 565-576, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34860318
17.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
BMC Med
; 20(1): 136, 2022 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-35462552
18.
Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
Jpn J Clin Oncol
; 52(10): 1124-1133, 2022 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35750038
19.
Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study.
Jpn J Clin Oncol
; 52(6): 545-553, 2022 May 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35296894
20.
Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2.
Int J Clin Oncol
; 27(2): 281-300, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022887